Erasca, Inc.

NasdaqGS:ERAS 株式レポート

時価総額:US$768.1m

Erasca 配当金

配当金 基準チェック /06

Erasca does not have a record of paying a dividend.

主要情報

n/a

配当利回り

-28.5%

バイバック利回り

総株主利回り-28.5%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当金アップデート

更新なし

Recent updates

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Oct 15
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca: New Focus After Restructuring, But Need More Differentiation

Sep 30

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Feb 21
Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

Nov 16
We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Jun 28
Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Jan 20
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Oct 20

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca adds 10% ahead of R&D Day

Sep 07

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Jul 18

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12
We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Dec 28
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

決済の安定と成長

配当データの取得

安定した配当: Insufficient data to determine if ERAS's dividends per share have been stable in the past.

増加する配当: Insufficient data to determine if ERAS's dividend payments have been increasing.


配当利回り対市場

Erasca 配当利回り対市場
ERAS 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (ERAS)n/a
市場下位25% (US)1.5%
市場トップ25% (US)4.5%
業界平均 (Biotechs)2.2%
アナリスト予想 (ERAS) (最長3年)0%

注目すべき配当: Unable to evaluate ERAS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

高配当: Unable to evaluate ERAS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


株主への利益配当

収益カバレッジ: Insufficient data to calculate ERAS's payout ratio to determine if its dividend payments are covered by earnings.


株主配当金

キャッシュフローカバレッジ: Unable to calculate sustainability of dividends as ERAS has not reported any payouts.


高配当企業の発掘